Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144339 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,993
- Enrollment target
- 20
- Study locations
NCT00144339: Completed Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
NCT00144339 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 5,993 participants, above the 963-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (522% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00144339, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,993 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.
Primary Outcome
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tiotropium
Study Locations (20)
California
- 205.235.3770 Boehringer Ingelheim Investigational Site - Carmichael
- 205.235.3778 Boehringer Ingelheim Investigational Site - Escondito
- 205.235.3810 Boehringer Ingelheim Investigational Site - Lakewood
- 205.235.3758 Boehringer Ingelheim Investigational Site - Long Beach
- 205.235.3812 Boehringer Ingelheim Investigational Site - Long Beach
- 205.235.3773 Boehringer Ingelheim Investigational Site - Los Angeles
- 205.235.3800 Boehringer Ingelheim Investigational Site - Los Angeles
- 205.235.3802 Boehringer Ingelheim Investigational Site - Los Angeles
- 205.235.3786 Pulmonary and Critical Care Medicine - Orange
- 205.235.3811 Boehringer Ingelheim Investigational Site - Palo Alto
- 205.235.3741 Boehringer Ingelheim Investigational Site - Rancho Mirage
- 205.235.3717 Boehringer Ingelheim Investigational Site - San Diego
- 205.235.3781 Boehringer Ingelheim Investigational Site - San Diego
- 205.235.3784 Boehringer Ingelheim Investigational Site - San Diego
- 205.235.3760 Boehringer Ingelheim Investigational Site - Sepulveda
Alabama
- 205.235.3779 Boehringer Ingelheim Investigational Site - Anniston
- 205.235.3785 Boehringer Ingelheim Investigational Site - Birmingham
- 205.235.3804 Boehringer Ingelheim Investigational Site - Jasper
- 205.235.3795 Boehringer Ingelheim Investigational Site - Mobile
Arizona
- 205.235.3759 Boehringer Ingelheim Investigational Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,993 participants |
| Start Date | 2002-12 |
| Phase | Phase 3 |
What the finished NCT00144339 record still lists
NCT00144339 is an interventional study that assigns participants to a tested intervention. Its 5,993 participants enrollment target places it among the larger protocols in the corpus, above the 963-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (522% higher).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00144339 names 20 study sites across 3 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00144339 about?
NCT00144339 is a clinical study titled "Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients". The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.
What is the current status of trial NCT00144339?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,993 participants. The study started on 2002-12.
What conditions does trial NCT00144339 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00144339?
The interventions under investigation include: placebo (DRUG), tiotropium (DRUG).
Who is sponsoring clinical trial NCT00144339?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144339 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00144339's enrollment target sits among peer trials
5,993 5th of 74 higher than 70 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
- NCT03127631 · 6,000 participants · NA
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- NCT03539705 · 6,000 participants
Food Allergy Registry at a Single Site
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia